We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

EKF Diagnostics

Manufactures analysers for the measurement of glucose, lactate, hemoglobin, hematocrit and HbA1c for GP surgeries, ph... read more Featured Products: More products

Download Mobile App





EKF Presents Cutting-Edge Point-Of-Care Diagnostic Solutions

By LabMedica International staff writers
Posted on 12 Nov 2024

EKF Diagnostics (Cardiff, Wales, UK) is attending MEDICA 2004 where the company is showcasing its diagnostic technologies and biotechnology solutions that empower healthcare and medical providers to make informed clinical decisions through point-of-care (POC) testing and life sciences applications. More...

EKF leads the way with cutting-edge POC diagnostic solutions that empower healthcare professionals and patients with rapid, accurate, and accessible testing capabilities and results. The company’s technologies enable informed decision-making, timely interventions, and improved patient outcomes at the POC. At this year’s MEDICA, EKF is demonstrating its POC medical devices and in-vitro diagnostic (IVD) tests for use at or near the patient’s location, engineered for fast and precise results, allowing healthcare professionals to make swift decisions. This includes EKF’s diabetes POC analyzers that measure glucose, lactate, glycated hemoglobin (HbA1C), and whole blood beta-hydroxybutyrate (BHB). These analyzers offer rapid and reliable results, giving practitioners and patients the critical information needed for clinical or lifestyle decisions within minutes. Among EKF’s diabetes point-of-care analyzers exhibited at MEDICA 2024 are Biosen C-Line, Quo-Test, STAT-Site WB, and Quo-Lab. The new Biosen C-Line, an advanced version of its industry-leading rapid benchtop glucose and lactate analyzer, has been designed to enhance usability with the latest color, touch screen, and advanced connectivity, enabling the device to seamlessly connect with hospital and laboratory IT systems, via EKF Link, to ensure patient results are quickly and securely available to clinicians.

EKF’s hemoglobin POC analyzers exhibited at MEDICA 2024 offer quick and convenient on-site blood testing, minimizing result turnaround times and enhancing patient diagnosis and outcomes. These include the DiaSpect Tm hand-held hemoglobin analyzer and Hemo Control POC hemoglobin analyzer that provides quantitative, lab-quality hemoglobin results after 25 seconds. Both devices are powered by EKF Link, which is an optional software platform that provides a flexible and secure method for connecting POC devices to hospital and laboratory IT systems. EKF Link is a middleware solution that helps healthcare providers manage their POC analyzers and associated data on one platform. A flexible and open solution that can be interfaced with most POC analyzers, allowing real-time data management, including patient test results, QC results, operator management, and analyzer configuration.

Related Links:
EKF Diagnostics


New
Gold Member
Latex Test
SLE-Latex Test
Serological Pipet Controller
PIPETBOY GENIUS
New
Plasmodium Test
Plasmodium DNA Real Time PCR Kit
New
cDNA Synthesis Kit
Ultimate cDNA Synthesis Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.